公开(公告)号：US07253179B2

公开(公告)日：2007-08-07

申请号：US10705173

申请日：2003-11-06

Applicant: Xi Chen ,  Xiaoqi Chen ,  Pingchen Fan ,  Juan Jaen ,  Leping Li ,  Jeffrey Thomas Mihalic

Inventor： Xi Chen ,  Xiaoqi Chen ,  Pingchen Fan ,  Juan Jaen ,  Leping Li ,  Jeffrey Thomas Mihalic

IPC: A61K31/4745 ,  C07D471/02

CPC classification number: C07D471/04

Abstract: Compounds, compositions and methods are provided that are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. In particular, the compounds of the invention are useful in the treatment and/or prevention of eating disorders, obesity, anxiety disorders and mood disorders.

Abstract translation: 提供了可用于治疗和/或预防由G蛋白偶联受体介导的病症或病症的化合物，组合物和方法。 特别地，本发明的化合物可用于治疗和/或预防进食障碍，肥胖症，焦虑障碍和情绪障碍。

公开(公告)号：US07079571B1

公开(公告)日：2006-07-18

申请号：US09415679

申请日：1999-10-08

Applicant: Xi Chen

Inventor： Xi Chen

IPC: H04B1/38

CPC classification number: H04L1/243

Abstract: A transceiver circuit having 10 mb and 100 mb transmit and receive circuitries using the power saving methods allows for power consumption of the transceiver circuit to be significantly reduced. This is accomplished by providing each defined subcircuit with its own power supply and means of activation and deactivation. However, the method for activating and deactivating digital subcircuits and analog subcircuits are different and therefore different types of control signals and methods are provided. Furthermore, there are two general types of power-saving situations. The first type is near total circuit power-down and the second type is partial circuit power-down. In yet another embodiment, a method for minimizing energy usage during the idle period is utilized.

Abstract translation: 使用省电方法的具有10mb和100mb发送和接收电路的收发器电路允许收发器电路的功耗显着降低。 这是通过为每个定义的子电路提供自己的电源以及激活和去激活的手段来实现的。 然而，用于激活和停用数字子电路和模拟子电路的方法是不同的，因此提供了不同类型的控制信号和方法。 此外，省电情况有两种。 第一种类型是接近总电路掉电，第二种是部分电路掉电。 在另一个实施例中，利用了一种在空闲时段期间最小化能量消耗的方法。

公开(公告)号：US06964866B2

公开(公告)日：2005-11-15

申请号：US09894630

申请日：2001-06-28

Applicant: C. Peter Romaine ,  Xi Chen

Inventor： C. Peter Romaine ,  Xi Chen

IPC: C12N15/80 ,  C12N1/14 ,  C12N1/16 ,  C12N1/18 ,  C12N15/74 ,  C12N15/82

CPC classification number: C12N15/80

Abstract: Applicants have devised a highly effective, convenient, and expeditious genetic transformation system for filamentous fungi, such as Agaricus bisporus. The preferred method uses an Agrobacterium-mediated transformation protocol. The critical features of this protocol include co-cultivation of the bacterium with fruit body tissue instead of spores. In a preferred embodiment, even higher transformation efficiencies were observed with the use of a homologous promoter in the polynucleotide expression construct in order to drive gene expression.

Abstract translation: 申请人设计了一种高效，方便，快速的丝状真菌如双孢蘑菇的遗传转化系统。 优选的方法使用农杆菌介导的转化方案。 该方案的关键特征包括将细菌与水果体组织而不是孢子共同培养。 在优选的实施方案中，为了驱动基因表达，在多核苷酸表达构建体中使用同源启动子观察到更高的转化效率。

公开(公告)号：US20050100982A1

公开(公告)日：2005-05-12

申请号：US10410897

申请日：2003-04-09

Applicant: Shawn DeFrees ,  David Zopf ,  Robert Bayer ,  Caryn Bowe ,  David Hakes ,  Xi Chen

Inventor： Shawn DeFrees ,  David Zopf ,  Robert Bayer ,  Caryn Bowe ,  David Hakes ,  Xi Chen

IPC: A61K38/00 ,  C07K1/00 ,  C07K1/107 ,  C07K1/13 ,  C07K9/00 ,  C07K14/505 ,  C12P21/06 ,  C07K14/745

CPC classification number: A61K47/48215 ,  A61K38/00 ,  A61K38/37 ,  A61K47/60 ,  C07K1/006 ,  C07K1/1077 ,  C07K1/13 ,  C07K9/00 ,  C07K14/505 ,  C07K14/755 ,  C12N9/644 ,  C12N9/96 ,  Y02A50/472

Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Abstract translation: 本发明包括用于重组肽分子的方法和组合物，包括向肽添加或缺失一个或多个糖基，和/或向肽中加入修饰基团。

公开(公告)号：US06429312B2

公开(公告)日：2002-08-06

申请号：US09812199

申请日：2001-03-19

Applicant: Jun Yuan ,  Xi Chen

Inventor： Jun Yuan ,  Xi Chen

IPC: C07D40914

CPC classification number: C07D409/12 ,  B32B15/08 ,  C07D333/76 ,  C08G73/10 ,  C08G73/1007 ,  C08G73/101 ,  H05K1/0346

Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof, wherein: R1, R2, R3, R4 are the same or different and represent hydrogen, C1-C6 alkyl, halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, trifluoromethoxy, C1-C6 alkoxy, —O2CR′, —NHCOR′, —COR′, —SOmR′, where R′ is C1-C6 alkyl and wherein m is 0, 1 or 2; or R1, R2, R3, R4 independently represent —CONR′R″, or —NR′R″ where R′ and R″ independently represent hydrogen or C1-C6 alkyl; R5 is hydrogen or C1-C6 alkyl; and R represents an aminoalkyl group, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

Abstract translation: 公开了下式的化合物或其药学上可接受的酸加成盐，其中：R 1，R 2，R 3，R 4相同或不同，表示氢，C 1 -C 6烷基，卤素，羟基，氨基，氰基，硝基，三氟甲基 ，三氟甲氧基，C 1 -C 6烷氧基，-O 2 CR'，-NHCOR'，-COR'，-SO m R'，其中R'是C 1 -C 6烷基，其中m是0,1或2; 或R 1，R 2，R 3，R 4独立地表示-CONR'R“，或-NR'R”，其中R'和R“独立地表示氢或C 1 -C 6烷基; R 5是氢或C 1 -C 6烷基; R代表氨基烷基，该化合物可用于治疗情感障碍如精神分裂症，抑郁症，阿尔茨海默氏病，运动障碍如帕金森综合征和肌张力障碍，以及其他对多巴胺能阻滞作用的药物滥用和强迫症。 此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。

公开(公告)号：US06291463B1

公开(公告)日：2001-09-18

申请号：US09345034

申请日：1999-06-30

Applicant: Xi Chen

Inventor： Xi Chen

IPC: A61K31496

CPC classification number: C07D277/82

Abstract: Disclosed are compounds of the formula: or pharmaceutically acceptable addition salts thereof wherein: R1 and R2 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano or trifluoromethyl; Ar represents aryl or heteroaryl, each of which is optionally substituted with R3, R4 and/or R4; R3, R4, and R6 independently represent hydrogen, halogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, perfluoro(C1-C6)alkyl, perfluoro(C1-C6)alkoxy, or SO2NH2; or R3 and R4 together with the atoms to which they are attached represent a ring having 5-7 atoms; and R5 represents hydrogen or C1-C6 alkyl, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

Abstract translation: 公开了下式的化合物或其药学上可接受的加成盐，其中：R 1和R 2相同或不同，表示氢，卤素，C 1 -C 6烷基，C 1 -C 6烷氧基，C 1 -C 6烷硫基，羟基， 或二（C 1 -C 6）烷基氨基，氰基或三氟甲基; Ar表示芳基或杂芳基，其各自任选被R 3，R 4和/或R 4取代; R 3，R 4和R 6独立地表示氢，卤素，羟基， C 1 -C 6烷氧基，全氟（C 1 -C 6）烷基，全氟（C 1 -C 6）烷氧基或SO 2 NH 2; 或R 3和R 4与它们所连接的原子一起表示具有5-7个原子的环; 并且R 5表示氢或C 1 -C 6烷基，该化合物可用于治疗和/或预防神经心理障碍，包括但不限于精神分裂症，躁狂症，痴呆，抑郁症，焦虑症，强迫行为，药物滥用，帕金森氏样运动 与使用神经安定药相关的疾病和运动障碍。

公开(公告)号：US5948802A

公开(公告)日：1999-09-07

申请号：US232874

申请日：1999-01-15

Applicant: Piyasena Hewawasam ,  Xi Chen ,  Min Ding ,  John E. Starrett, Jr.

Inventor： Piyasena Hewawasam ,  Xi Chen ,  Min Ding ,  John E. Starrett, Jr.

IPC: C07D271/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61P1/06 ,  A61P9/00 ,  A61P9/10 ,  A61P11/06 ,  A61P13/02 ,  A61P15/00 ,  A61P15/10 ,  A61P25/00 ,  A61P25/06 ,  A61P25/08 ,  A61P43/00 ,  C07D271/06 ,  C07D271/07 ,  C07D271/113

CPC classification number: C07D271/07

Abstract: The present invention provides novel benzoate derivatives having the general formula ##STR1## wherein R is as defined herein, or a nontoxic pharmaceutically acceptable salt or solvate thereof and are useful in the treatment of disorders which are responsive to the opening of potassium channels.

Abstract translation: 本发明提供具有通式的新颖苯甲酸酯衍生物，其中R如本文所定义，或其无毒的药学上可接受的盐或溶剂化物，并且可用于治疗对钾通道开放有响应的病症。

公开(公告)号：US5922879A

公开(公告)日：1999-07-13

申请号：US995971

申请日：1997-12-22

Applicant: Xi Chen ,  Jan William Francis Wasley

Inventor： Xi Chen ,  Jan William Francis Wasley

IPC: C07D295/12 ,  A61K31/44 ,  A61K31/495 ,  A61P25/00 ,  A61P25/18 ,  A61P25/20 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  C07D211/70 ,  C07D215/40 ,  C07D295/13 ,  C07D211/06 ,  C07D211/68 ,  C07D211/80

CPC classification number: C07D295/13 ,  C07D211/70 ,  C07D215/40

Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable acid addition salts thereof wherein:R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 are the same or different and represent hydrogen, halogen, alkyl, alkoxy, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy; --O.sub.2 CR', --NHCOR', --COR', --SO.sub.m R', where R' is C.sub.1 -C.sub.6 alkyl and wherein m is 0, 1 or 2; orR.sub.1 R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 independently represent --CONR'R", or --NR'R" where R' and R" independently represent hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.8 is hydrogen or lower alkyl;X represents an optionally substituted alkylene group; andY represents a mono-, di- or trisubsituted cyclic amino group,which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

Abstract translation: 公开了下式的化合物或其药学上可接受的酸加成盐，其中：R1，R2，R3，R4，R5，R6和R7相同或不同，代表氢，卤素，烷基，烷氧基，羟基，氰基， 硝基，三氟甲基，三氟甲氧基; -O2CR'， - NHCOR'， - COR'，-SOmR'，其中R'是C1-C6烷基，其中m是0,1或2; 或R 1，R 2，R 3，R 4，R 5，R 6和R 7独立地表示-CONR'R“或-NR'R”，其中R'和R“独立地表示氢或C1-C6烷基; R8是氢或低级烷基; X表示任选取代的亚烷基; Y代表单，二或三取代的环状氨基，该化合物可用于治疗情感障碍如精神分裂症，抑郁症，阿尔茨海默病，运动障碍如帕金森综合征和肌张力障碍，以及其他对多巴胺能阻滞作用的疾病 例如药物滥用和强迫症。 此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。

公开(公告)号：US5910586A

公开(公告)日：1999-06-08

申请号：US965275

申请日：1997-11-06

Applicant: Xi Chen ,  Jun Yuan ,  Andrew Thurkauf

Inventor： Xi Chen ,  Jun Yuan ,  Andrew Thurkauf

IPC: A61K31/44 ,  A61K31/4427 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/473 ,  A61K31/495 ,  A61K31/535 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D221/10 ,  C07D401/12 ,  C07D409/12 ,  C07D471/04 ,  C07D498/04 ,  C07D241/38 ,  C07D273/04 ,  C07D285/15

CPC classification number: C07D401/12 ,  C07D221/10 ,  C07D409/12 ,  C07D471/04

Abstract: Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof wherein: R.sub.1 -R.sub.4 represent organic or inorganic groups;A represents an alkylene group of 2 to 6 carbon atoms optionally substituted with one or more, alkyl groups having from 1 to 4 carbon atoms;Y represents methylene, oxygen, sulfur, or NH; andX is either N, C or CH,which compounds are, useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

Abstract translation: 公开了下式的化合物或其药学上可接受的酸加成盐，其中：R 1 -R 4表示有机或无机基团; A表示任选被一个或多个具有1至4个碳原子的烷基取代的2至6个碳原子的亚烷基; Y表示亚甲基，氧，硫或NH; X是N，C或CH，这些化合物可用于治疗情感障碍如精神分裂症，抑郁症，阿尔茨海默病，运动障碍如帕金森综合征和肌张力障碍，以及其他对多巴胺能阻滞作用的药物滥用 和强迫症。 此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。

公开(公告)号：US5688950A

公开(公告)日：1997-11-18

申请号：US636662

申请日：1996-04-23

Applicant: Xi Chen ,  Jun Yuan ,  Andrew Thurkauf

Inventor： Xi Chen ,  Jun Yuan ,  Andrew Thurkauf

IPC: A61K31/44 ,  A61K31/4427 ,  A61K31/4433 ,  A61K31/47 ,  A61K31/473 ,  A61K31/495 ,  A61K31/535 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  A61P43/00 ,  C07D221/10 ,  C07D401/12 ,  C07D409/12 ,  C07D471/04 ,  C07D498/04 ,  C07D221/06 ,  C07D241/36 ,  C07D241/40

CPC classification number: C07D401/12 ,  C07D221/10 ,  C07D409/12 ,  C07D471/04

Abstract: Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof wherein: R1-R.sub.4 represent organic or inorganic groups; A represents an alkylene group of 2 to 6 carbon atoms optionally substituted with one or more alkyl groups having from 1 to 4 carbon atoms;Y represents methylene, oxygen, sulfur, or NH; and X is either N, C or CH, which compounds are useful in the treatment of affective disorders such as schizophrenia, depression, Alzheimer's disease, movement disorders such as Parkinsonism and dystonia, and other disorders which respond to dopaminergic blockade such as substance abuse and obsessive compulsive disorders. Further, compounds of this invention may be useful in treating the extrapyramidal side effects associated with the use of conventional neuroleptic agents.

Abstract translation: 公开了下式的化合物或其药学上可接受的酸加成盐，其中：R 1 -R 4表示有机或无机基团; A表示任选被一个或多个具有1至4个碳原子的烷基取代的2至6个碳原子的亚烷基; Y表示亚甲基，氧，硫或NH; X是N，C或CH，这些化合物可用于治疗情感障碍如精神分裂症，抑郁症，阿尔茨海默氏病，运动障碍如帕金森综合征和肌张力障碍，以及其他对多巴胺能阻滞作用的药物滥用等疾病， 强迫症强迫症 此外，本发明的化合物可用于治疗与使用常规精神抑制剂相关的锥体束外副作用。